Free shipping on all orders over $ 500

LY2510924

Cat. No. M10230

All AbMole products are for research use only, cannot be used for human consumption.

LY2510924 Structure
Synonym:

LY-2510924

Size Price Availability Quantity
5mg USD 300  USD300 In stock
10mg USD 460  USD460 In stock
25mg USD 900  USD900 In stock
50mg USD 1480  USD1480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM. LY2510924 inhibits SDF-1-induced cell migration (IC50 = 0.26 nM) in human lymphoma U937 cells expressing endogenous CXCR4. LY2510924 chiefly inhibits the proliferation of AML cells with little induction of cell death and reduces protection against chemotherapy by stromal cells.

Protocol (for reference only)
Cell Experiment
Cell lines U937 cells
Preparation method Briefly, U937 cells were harvested and washed once with chemotaxis assay buffer prepared with 1× RPMI medium containing 10 mmol/L HEPES, pH 7.5, and 0.3% BSA. Cells were then resuspended in assay buffer at a density of 5 × 106 cells/mL. The assay was performed in a 96-well ChemoTx plate (NeuroProbe). Generally, 50 μL of cell mixture with or without LY2510924 was plated on the upper chamber, and 30 μL of SDF-1α (10 ng/mL) prepared in 1× chemotaxis buffer was added to the lower chamber. The plate was then incubated for 2.5 hours at 37°C. Following the incubation, 5 μL of CellTiter 96 AQ (Promega) was added into the lower chamber. The plate was then incubated for 60 minutes at 37°C. The migrated cells were detected by measuring the absorbance at 492 nm with a Tecan Spectrafluor Plus Microplate Reader.
Concentrations 0-10 uM
Incubation time 2.5 h
Animal Experiment
Animal models female C57/BL6 mice, male Sprague-Dawley rats, male Beagle dogs, and male Cynomolgus monkeys at fasted state
Formulation formulated in 1× PBS
Dosages 3 mg/kg
Administration s.c. or i.v.
Chemical Information
Molecular Weight 1189.45
Formula C62H88N14O10
CAS Number 1088715-84-7
Solubility (25°C) Water 45 mg/mL
DMSO 120 mg/mL
Storage -20°C, sealed
References

[1] Byung-Sik Cho, et al. Blood. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

[2] Sheng-Bin Peng, et al. Mol Cancer Ther. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models

Related CXCR Products
Elubrixin

Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

VUF 11222 

VUF 11222 is a CXCR3 non-peptide-like agonist.

(±)-AMG 487 

(±)-AMG 487 is a racemate of AMG 487.

Elubrixin tosylate

Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

Elubrixin hydrochloride

Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: LY2510924, LY-2510924 supplier, CXCR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.